REQUEST PRICE

Fields with * are required
Premium Phosphosite-Specific 7TM Antibodies
Novel Tools for Your GPCR Research
Select Your Country of Delivery below

Corticotropin-Releasing Factor Receptor Antibodies

Corticotropin-releasing factor receptors are activated by the endogenous peptides corticotrophin-releasing hormone (CRF), urocortin 1 (UCN1), urocortin 2 (UCN2) and urocortin 3 (UCN3). CRF1 and CRF2 receptors are activated non-selectively by CRF and UCN1. CRF2 receptors are selectively activated by UCN2 and UCN3. CRF1 receptors are selectively antagonized by small molecules NBI27914, R121919, antalarmin, CP 154,526, CP 376,395. CRF2 receptors are selectively antagonized by antisauvagine and astressin 2B. CRF-induced activation of brain CRF1 receptors is both necessary and sufficient to define the stress response. Agonist stimulation of both CRF1 and CRF2 normally leads to stimulation of intracellular cyclic AMP accumulation by coupling to Gs proteins.

Close filters
No results were found for the filter!
NEW
Validation of the Corticotropin-Releasing Factor Receptor 1 in transfected HEK293 cells
CRF1 (non-phospho-Corticotropin-Releasing...
The non-phospho-CRF1 receptor antibody is directed against the distal part of the carboxyl-terminal tail of human CRF1. It can be used to detect total CRF1 receptors in Western blots independent of phosphorylation. The non-phospho-CRF1...
$ 350.00
Details
NEW
Agonist-induced Threonine428/Serine429 phosphorylation of CRF1 Receptor
pT428/pS429-CRF1...
Threonine428/Serine429 (T428/S429) is a major phosphorylation site of the CRF1 receptor. The pT428/pS429-CRF1 antibody detects phosphorylation in response to high-efficacy agonists. T428/S429 phosphorylation is a key regulator of CRF1...
$ 350.00
Details
NEW
Agonist-induced Threonine431 phosphorylation of CRF1 Receptor
pT431-CRF1 (phospho-Corticotropin-Releasing...
Threonine431 (T431) is a major phosphorylation site of the CRF1 receptor. The pT431-CRF1 antibody detects phosphorylation in response to high-efficacy agonists. T431 phosphorylation is a key regulator of CRF1 desensitization, β-arrestin...
$ 350.00
Details
NEW
Agonist-induced Serine434/Serine437 phosphorylation of CRF1 Receptor
pS434/pS437-CRF1...
Serine434/Serine441 (S437/S441) is a major phosphorylation site of the CRF1 receptor. The pS434/pS437-CRF1 antibody detects phosphorylation in response to high-efficacy agonists. S434/S437 phosphorylation is a key regulator of CRF1...
$ 350.00
Details

For more information on chemokine receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM. International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev. 2003 Mar;55(1):21-6. doi: 10.1124/pr.55.1.3. PMID: 12615952.

Dautzenberg FM, Grigoriadis DE, Hauger RL, Risbrough VB, Steckler T, Vale WW, Valentino RJ. Corticotropin-releasing factor receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE. 2019; 2019(4).

For more information on chemokine receptor pharmacology please refer to the  IUPHAR  database. For further reading refer to: Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale... read more »
Close window
Corticotropin-Releasing Factor Receptor Antibodies

For more information on chemokine receptor pharmacology please refer to the IUPHAR database. For further reading refer to:

Hauger RL, Grigoriadis DE, Dallman MF, Plotsky PM, Vale WW, Dautzenberg FM. International Union of Pharmacology. XXXVI. Current status of the nomenclature for receptors for corticotropin-releasing factor and their ligands. Pharmacol Rev. 2003 Mar;55(1):21-6. doi: 10.1124/pr.55.1.3. PMID: 12615952.

Dautzenberg FM, Grigoriadis DE, Hauger RL, Risbrough VB, Steckler T, Vale WW, Valentino RJ. Corticotropin-releasing factor receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database. IUPHAR/BPS Guide to Pharmacology CITE. 2019; 2019(4).

Recently viewed